Rubicon Research IPO
Rubicon Research IPO
Rubicon Research Limited, established in 1999, is a pharmaceutical formulations company focused on innovation through R&D, specializing in complex generics and drug-device combination products for highly regulated markets, primarily the United States. The company is among the fastest-growing Indian formulations companies, with a strong focus on high-margin specialty products. As of June 2025, Rubicon had 72 active ANDA/NDA approvals from the US FDA, with a high commercialization rate of 86.4%. It operates two US FDA-inspected R&D centers (India and Canada) and three manufacturing facilities in India, maintaining a strong regulatory compliance track record. The fresh issue proceeds will be used primarily for debt repayment and funding strategic inorganic growth initiatives.
Investment Timeline
🤖 Smart Analysis
*AI score is algorithmic and for educational purposes only.
🎯 Application Strategy
Action: 👍 CONSIDER - Decent opportunity for diversification
Lots: Apply 1-2 lots based on risk appetite
⏳ Timing Advice
⚡ URGENT: Apply on DAY 1 MORNING - Extremely high demand! Allotment probability very low
Key Factor Analysis
Issue Details
Object of the Issue
The company proposes to utilize the Net Proceeds from the Issue towards the following objects:
- Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by the Company (₹310 crores).
- Funding inorganic growth through unidentified acquisitions and other strategic initiatives.
- General corporate purposes.
Frequently Asked Questions
What is the current GMP of Rubicon Research IPO?
What is the AI Prediction for Rubicon Research IPO?
When will the allotment for Rubicon Research IPO be announced?
What is the listing date for Rubicon Research IPO?
Liability Disclaimer: Ipofly.com is an informational platform. We are not SEBI registered. The information provided here (including GMP and AI analysis) is for educational purposes only and should not be considered financial advice. Investments in the stock market are subject to market risks. Please consult your financial advisor before investing.